American Academy of Dermatology

American academy of dermatology survey shows generation z adults are unfamiliar with sunburn and tanning risks

Retrieved on: 
Tuesday, May 9, 2023
Generation Z, Bleeding, Gen, Life, Skin cancer, Clothing, SPF, American Academy, Private practice, Mentorship, Smash Mouth, Tanning, FAAD, Stomach, Swimming, UPF, Patient, AAD, Risk, UV, Melanoma, Water, American Academy of Dermatology, Perspiration, Sunburn, Skin, Dietary supplement, Cosmetics

ROSEMONT, Ill., May 9, 2023 /PRNewswire/ -- A recent American Academy of Dermatology survey of more than 1,000 U.S. adults revealed that many Generation Z adults, ages 18-25, are unaware of the risks associated with overexposure to the sun and believe tanning myths. In recognition of Skin Cancer Awareness Month this May, the AAD encourages everyone to practice safe sun to protect themselves from the sun's harmful rays and reduce their risks of developing skin cancer.

Key Points: 
  • ROSEMONT, Ill., May 9, 2023 /PRNewswire/ -- A recent American Academy of Dermatology survey of more than 1,000 U.S. adults revealed that many Generation Z adults, ages 18-25, are unaware of the risks associated with overexposure to the sun and believe tanning myths.
  • According to the survey, 71% of Gen Z adults are unfamiliar with the risks associated with sunburn, with 40% being unaware of tanning risks and 59% believing tanning myths, such as tanning is healthy, and a base tan will prevent sunburn.
  • Tanning is a risk factor for skin cancer, but 20% of Gen Z adults say that getting a tan is more important to them than preventing skin cancer.
  • In fact, 30% said that it is worth looking great now even if it means looking worse later in life.

Stony Brook University Hospital and The Mollie Biggane Melanoma Foundation Promote Skin Cancer Prevention Through New Inpatient Initiative

Retrieved on: 
Tuesday, May 9, 2023
Partnership, Doctor of Education, American Academy of Dermatology, Education, Nursing, Skin, Skin cancer, Healthgrades, American Academy, CNS, Melanoma, Electronic health record, MS, Incidence, Hospital, Patient, Cancer, RN, Stony Brook University Hospital, Health, Regulation, Disease, Dermatology

GARDEN CITY, N.Y., May 9, 2023 /PRNewswire/ -- Stony Brook University Hospital (SBUH), the only hospital on Long Island ranked by Healthgrades among the top 1% of hospitals in the nation, and the Mollie Biggane Melanoma Foundation announce their collaboration to provide Stony Brook patients with skin cancer education through their inpatient Electronic Medical Records program.

Key Points: 
  • GARDEN CITY, N.Y., May 9, 2023 /PRNewswire/ -- Stony Brook University Hospital (SBUH), the only hospital on Long Island ranked by Healthgrades among the top 1% of hospitals in the nation, and the Mollie Biggane Melanoma Foundation announce their collaboration to provide Stony Brook patients with skin cancer education through their inpatient Electronic Medical Records program.
  • Now, SBUH nurses will also evaluate the skin of all patients for skin lesions and cancers, as well as educate them on skin cancer and protective behaviors.
  • "We gladly join forces with the Mollie Biggane Melanoma Foundation in this important effort," said Santora.
  • This initiative is momentous because more people are diagnosed with skin cancer in the U.S. than all other cancers combined.

Almirall’s First Quarter 2023 Results

Retrieved on: 
Monday, May 8, 2023
Biotechnology, Pharmaceutical, Health, The New England Journal of Medicine, Medical journal, Safety, Atopic dermatitis, JAMA Dermatology, BJD, Acquisition, Patient, MM, Ciclosporin, Ageing, Disease, Tildrakizumab, Science, American Academy of Dermatology, Face, Pharmacokinetics, Scalp, Advantage, EMA, Titan IIIB, BMJ, Growth, III, Psoriasis, Autoimmune disease, Accounting, Traction, Administration, AAD, Adolescence, American Academy, TRX, Almirall, Trial of the century, NEJM, Advocate, EBITDA, AD, Fine chemical, Medical imaging, Mobile phone, Pharmaceutical industry, Vaccine, EU, Dermatology

We delivered an excellent operational performance that sets us on track to meet our 2023 guidance.

Key Points: 
  • We delivered an excellent operational performance that sets us on track to meet our 2023 guidance.
  • We remain focused on preparing the business for the expected approval of lebrikizumab in late 2023, a product with the potential to transform our company.
  • Almirall is confident that its European business will continue to flourish throughout 2023 with the contribution of new countries where Ilumetri® has been recently launched.
  • In the first quarter of 2023, Almirall announced several positive clinical updates on lebrikizumab.

DermTech Reports First-Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 4, 2023
Biotechnology, Health, Oncology, DMT, ASP, VI, Marketing, Skin, Skin cancer, RNA, American Academy, Dermatology, Collection, AAD, American Academy of Dermatology, Webcast, Research, Carcinoma, Cryptocurrency, Video game

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its first-quarter 2023 financial results.

Key Points: 
  • DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its first-quarter 2023 financial results.
  • “In the last few months, we had excellent overall progress with payers and strong execution by our commercial organization,” said John Dobak, M.D., CEO, DermTech.
  • “We expanded coverage for the DermTech Melanoma Test (DMT) by nearly 40 percent since the end of 2022.
  • In March 2023, the Company presented four new posters at the 2023 American Academy of Dermatology (AAD) Annual Meeting.

Dr. Weily Soong Appointed Chief Research Innovation Officer for AllerVie Clinical Research

Retrieved on: 
Tuesday, May 2, 2023
Health, Hospitals, Other Health, General Health, Research, Science, Yale University, Asthma, American Academy of Dermatology, American Academy, Publication, Patient, Clinical research, Internal medicine, Immunology, Pharmaceutical industry, Nursing, Allergy

AllerVie Clinical Research , an affiliate of AllerVie Health and a nationally recognized network of clinical research sites, today announced the appointment of Dr. Weily Soong as its new chief research innovation officer.

Key Points: 
  • AllerVie Clinical Research , an affiliate of AllerVie Health and a nationally recognized network of clinical research sites, today announced the appointment of Dr. Weily Soong as its new chief research innovation officer.
  • Formerly AllerVie’s chief medical officer, Soong will lead the company’s efforts to drive innovation through the advancement of new therapies and diagnostics for asthma, allergies and other related immunological conditions at AllerVie Clinical Research.
  • “I’m thrilled for the opportunity to work with such a strong team to continue advancing AllerVie’s Clinical Research division forward,” said Soong.
  • “In his new role, Dr. Soong’s deep understanding of allergy and asthma-related clinical research studies will be invaluable as we continue to grow our company and advance the clinical research field,” said Chris Roussos, CEO of AllerVie Health.

This Week in Health News: 10 Stories You Need to See

Retrieved on: 
Friday, April 28, 2023
Risk, American Academy of Dermatology, EVP, Medtronic, Skin cancer, Business, Mightier, American Academy, Toxicity, Melanoma, Patient, Susan, AAD, Mental, PR Newswire, Breast cancer, Disease, News, Birth control, Medicaid, Dermatology

NEW YORK, April 28, 2023 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists covering the healthcare industry stay on top of the week's most newsworthy and popular releases, here's a roundup of stories from the week that shouldn't be missed.

Key Points: 
  • A roundup of the week's most newsworthy health industry press releases from PR Newswire, including parents' dissatisfaction with pediatric mental health benefits.
  • NEW YORK, April 28, 2023 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire.
  • To help journalists covering the healthcare industry stay on top of the week's most newsworthy and popular releases, here's a roundup of stories from the week that shouldn't be missed.
  • To combat these growing concerns, Mightier has launched "Mightier for Business" that provides employers, health plans (both commercial and Medicaid) and digital health partners a solution to immediate access to pediatric mental health services.

Golden State Dermatology Expands Their Network in Los Angeles

Retrieved on: 
Tuesday, April 25, 2023
Insurance, David Geffen School of Medicine at UCLA, San Francisco Bay Area, Partnership, American Academy of Dermatology, Skin cancer, Ageing, GSD, FNP, American Academy, Research, Smash Mouth, BSN, Doctor of Philosophy, MS, American Board of Commissioners for Foreign Missions, Patient, Physician, Los, UCLA, Society, Harbor, Veterinary medicine, Dermatology, MD, RN

LOS ANGELES, April 25, 2023 /PRNewswire/ -- Golden State Dermatology (GSD) is pleased to announce a new partnership with the dermatology practice Moy-Fincher-Chipps Facial Plastics/Dermatology, with three locations in the Los Angeles area. The new partnership expands GSD's footprint from the Bay Area and California's Central Valley into Southern California.

Key Points: 
  • LOS ANGELES, April 25, 2023 /PRNewswire/ -- Golden State Dermatology (GSD) is pleased to announce a new partnership with the dermatology practice Moy-Fincher-Chipps Facial Plastics/Dermatology, with three locations in the Los Angeles area.
  • The practice specializes in medical dermatology, cosmetic dermatology, cosmetic and facial plastic surgery, and skin cancer treatments.
  • The Los Angeles-area clinics are located at:
    GSD offers more than 30 convenient locations throughout Northern California, the Central Valley, and the Los Angeles area and accepts most forms of insurance.
  • To learn more about Golden State Dermatology, please visit GoldenStateDermatology.com .

MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today

Retrieved on: 
Wednesday, April 19, 2023
Inflammation, Q&A, Medical college, Clinical trial, American Academy, EDT, AAD, CEST, American Academy of Dermatology, Medical College of Wisconsin, Webcast, BST, Pharmaceutical industry, Dermatology

ZUG, Switzerland, April 19, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host today its Capital Markets Day for investors and analysts in New York and virtually.

Key Points: 
  • ZUG, Switzerland, April 19, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host today its Capital Markets Day for investors and analysts in New York and virtually.
  • The live event will be held in New York, US, with a webcast available for virtual attendees, from 10:30-12:30 EDT (15:30-17:30 BST / 16:30-18:30 CEST).
  • Top-line results for a Phase 2 trial of sonelokimab in moderate-to-severe hidradenitis suppurativa are expected around the end of June 2023 with final read-out by Q4 2023.
  • Patient enrollment in a global Phase 2 trial in psoriatic arthritis is on schedule with primary end-point readout expected at the end of 2023.

Florida Medical Clinic Welcomes Dermatologist Felicia Hall, MD

Retrieved on: 
Tuesday, April 18, 2023
Music, American Academy of Dermatology, University, Diet, Education, Zinc, Titanium, Skin cancer, Cancer, American Academy, Vanderbilt University, American Medical Association, Patient, Reading, Society, Skin, Medical device, Dermatology, Dermatopathology

Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Florida Medical Clinic is pleased to welcome Dr. Felicia Hall to its Dermatology Department in Carrollwood, where she joins Dr. Rachel Careccia , Ellen Lockwood, PA-C and Heather Leto, APRN-C.

Key Points: 
  • Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Florida Medical Clinic is pleased to welcome Dr. Felicia Hall to its Dermatology Department in Carrollwood, where she joins Dr. Rachel Careccia , Ellen Lockwood, PA-C and Heather Leto, APRN-C.
  • She then returned to Florida for both medical school and her Dermatology residency at the University of South Florida in Tampa.
  • Florida Medical Clinic is proud to include over 380 providers and nearly 2,000 employees in more than 50 locations across Florida’s East Pasco and Hillsborough counties.
  • Florida Medical Clinic doctors offer care in more than 40 different medical specialties.

Minghui Pharmaceutical Inc. Announces Phase 2 Clinical Trial Success of MH004 Cream as a Potential Best-in-Class Topical Treatment for Mild-to-Moderate Atopic Dermatitis and the FDA Clearance of its Global Phase 3 MRCT

Retrieved on: 
Friday, April 14, 2023
Cream, Communication, Royal college, American Academy of Dermatology, BSA, College of Physicians and Surgeons of Ontario, JAK, Physician, Cancer, Pharmacokinetics, American Academy, Atopic dermatitis, Phase 2 (graffiti artist), Liu Minghui, Șaeș, Alopecia areata, Incidence, IGA, Royal College of Physicians and Surgeons of Canada, Surgeon, Prurigo nodularis, Vitiligo, AD, FDA, IND, Safety, Body surface area, Vaccine, Pharmaceutical industry, EASI

The study assessed safety, tolerability, pharmacokinetics (PK) and efficacy of two strengths of MH004 Cream.

Key Points: 
  • The study assessed safety, tolerability, pharmacokinetics (PK) and efficacy of two strengths of MH004 Cream.
  • "MH004 Cream is a topical cream containing a JAK inhibitor that was designed with Minghui's proprietary technology and formulation.
  • Based on the current phase 2 results, we plan to further pursue the development of MH004 Cream in atopic dermatitis as well as other dermatological diseases."
  • On April 1, the company received FDA IND approval for AD Phase 3 MRCTs after successful FDA communication and IND submission.